Navigation Links
Phosphagenics to Commence Phase 2 TPM/Insulin Clinical Trial
Date:9/12/2007

MELBOURNE, Australia, Sept. 12 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that it has received approval to commence a Phase 2 clinical trial of its proprietary transdermal insulin, TPM/Insulin.

The Phase 2 trial, to commence this month, will be single-blinded, placebo controlled, three way cross-over and randomized in up to 60 patients, with the endpoint of assessing the efficacy of TPM/Insulin in patients with type 1 and type 2 diabetes.

The trial, which will be conducted by CMAX at The Royal Adelaide Hospital under the guidance and supervision of Dr. Sepehr Shakib, Director, Department of Clinical Pharmacology, Royal Adelaide Hospital and Associate Professor William Hsu of the Joslin Diabetes Centre, Harvard Medical School, is expected to be completed in the first half of 2008.

Dr. Esra Ogru, Executive Vice President of Research and Development at Phosphagenics, said: "We are excited to reach this milestone and advance our technology for the transdermal delivery of insulin to Phase 2 trials.

"Our Phase 1b trial, conducted by CMAX at the Royal Adelaide Hospital, showed that our TPM/Insulin formulation safely penetrated through human skin and delivered insulin into the blood stream over a sustained period of time without adverse reactions.

"Phosphagenics' aim is to provide a safe and effective transdermal insulin to treat diabetes," concluded Dr. Ogru.

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. The Company's core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutr
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... their offering. The Central Nervous System (CNS) ... of pharmaceuticals industry. The numbers of CNS disorders have increased ... to meet the market requirements. There has been steady to ... the past two decades. The market for CNS therapies is ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
(Date:8/30/2014)... Phoenix, AZ (PRWEB) August 30, 2014 ... experienced personal injury attorneys located throughout Arizona is pleased ... settlement. This is one specific example among many cases ... that clients are able to retain a greater portion ... case after case that providing a positive solution for ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Serving contented ... in India, Profit By Outsourcing is now offering ... services. The company gives emphasize on putting forward the ... product to clients. Their dedicated team of professionals and ... results. They can handle even the critical issues of ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:8/30/2014)... Delhi, India (PRWEB) August 30, 2014 ... online reputation management industry, has announced to offer guarantee ... has decided to offer this guarantee because of its ... more than 200 clients from all over the world ... doing extremely good job. , On being asked ...
(Date:8/30/2014)... When a prominent bank reveals a successful cyber attack, ... 27th, when news began surfacing about the FBI probing ... and at least one other bank. But when news gets ... seven prominent banks , everyone starts thinking about their own ... quickly goes viral. Bloomberg followed up on Friday with ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Removecomplaints.net Announces Guaranteed Complaints Removal Services 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5
... Goodwin HealthDay Reporter , THURSDAY, May 10 ... children have little or no label information about drug ... "We still have a long way to go," ... of the U.S. Food and Drug Administration,s Office of ...
... , THURSDAY, May 10 (HealthDay News) -- A ... U.S. Food and Drug Administration showed promising results in ... took Qnexa, a combination of the drugs phentermine and ... many weight-related health problems, the study found. The findings ...
... a low haemoglobin (Hb) level do not respond well to ... survival are compromised. Now researchers from The Netherlands have found ... can be overcome by the use of a treatment known ... carbogen (a mixture of carbon dioxide and oxygen) and the ...
... privately insured colon cancer patients found that managed care presence ... surgery to treat colon cancer lowered costs, a national team ... University School of Public Health and Health Services reported in ... cancer is the second leading cause of cancer death in ...
... 2012) A review of 30 years of life-threatening asthma ... annual ICU admissions for the condition have dropped 74 percent. ... cases at University Hospital between 1980 and 2010, also showed ... not result in longer hospital stays. UT Medicine is ...
... severe complications from systemic sclerosis, also known as scleroderma, ... Rheumatism , a journal of the American College of ... were more likely to have antibodies that increased frequency ... decreased survival. According to the ACR there ...
Cached Medicine News:Health News:Only Half of Meds Taken by Kids Have 'Adequate' Safety Info: Study 2Health News:Only Half of Meds Taken by Kids Have 'Adequate' Safety Info: Study 3Health News:New Weight-Loss Drug Shows Promise in Trial 2Health News:New Weight-Loss Drug Shows Promise in Trial 3Health News:Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels 2Health News:Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels 3Health News:Economic theory actually works in health care 2Health News:ICU stays for worst asthma drop 74 percent, review finds 2Health News:Systemic sclerosis complications more severe in African Americans than Caucasians 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: